Researchers at the University of Nebraska Medical Center have identified a key cell signaling pathway that drives the devastating muscle loss, or cachexia, suffered by many cancer patients. The study, which will be published ...
May 22, 2020
0
27
Exercise and physical therapy often are recommended to help people who have arthritis. Both can strengthen muscle—a benefit that also can reduce joint pain. But building muscle mass and strength can take many months and ...
May 8, 2020
0
371
When an actor is unable to perform in the theatre, an understudy—ideally one with some practice in the role—can take her place on stage. A study from Dr. Bernard Jasmin's laboratory at the University of Ottawa and published ...
Apr 24, 2020
0
54
Cancer cachexia is a complex metabolic disease accounting for approximately one third of all cancer-related deaths worldwide. So far, there is no effective therapy for this muscle wasting disease. Researchers from the Leibniz ...
Feb 25, 2020
0
1
Researchers identified a group of small molecules that may open the door to developing new therapies for Duchenne muscular dystrophy (DMD), an as-yet-uncured disease that results in devastating muscle weakening and loss. ...
Feb 24, 2020
0
129
Duchenne type muscular dystrophy (DMD) is the most common hereditary muscular disease among children, leaving them wheelchair-bound before the age of 12 and reducing life expectancy. Researchers at Technical University of ...
Jan 28, 2020
0
240
A Rutgers-led team may have found the key to preventing Duchenne muscular dystrophy (DMD)-related heart disease, the leading cause of death in patients living with the disease.
Jan 14, 2020
3
9
Research led by Professor Steve Wilton and Professor Sue Fletcher and licensed to Sarepta Therapeutics has delivered a second treatment for Duchenne muscular dystrophy, with the drug gaining accelerated approval by the U.S. ...
Jan 8, 2020
0
14167
The causes of rare diseases could be uncovered using an approach created to identify genetic mutations that trigger a muscle-wasting condition, a study suggests.
Dec 18, 2019
0
13
(HealthDay)—In a head-to-head study of mineralocorticoid receptor antagonists, spironolactone was found to be noninferior to eplerenone for slowing the progression of heart damage in boys with Duchenne muscular dystrophy ...
Oct 28, 2019
0
5
